To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 µg + Glycopyrrinium 50 µg versus Tiotropium 9 µg + Formoterol 12 µg in Patients with Chronic Obstructive Airway Disease
Annals of African Medicine · 2025
DOI: 10.4103/aam.aam_120_24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of African Medicine, 2025. Verfasst von Javeeria Shabbir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Bronchodilator Agents, Formoterol Fumarate, Glycopyrrolate, Indans. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
The efficacy and safety of once-daily fixed-dose combination of indacaterol maleate (IND) 110 µg with glycopyrronium 25 µg (GLY) via Rotahaler device versus tiotropium (TRP) 9 µg + formoterol (FOR) 112 µg was evaluated in patients with chronic obstructive airway disease.
Objective
(1) To study and compare the effect of inhaled IND/GLY (110/50 µg) once-daily (OD) fixed-dose combination versus FOR/TRP (9/12 µg) twice daily (BD) on lung function in chronic obstructive pulmonary disease (COPD) patients by evaluating forced expiratory volume in 1 s (FEV1), 1 h postinhalation on days 28 th , 56 th , and 84 th of the treatment. (2) To assess patient-reported outcomes (PROs) using COPD assessment test (CAT) scores, intake of rescue medications, and frequency of exacerbations. Materials and Methods: In this prospective observational comparative study, patients were randomly assigned in a 1:1 ratio to two sequences: sequence 1 ( n = 50) receiving IND/GLY (110/50 µg) once daily and sequence 2 ( n = 50) receiving TRP/FOR (9/12 µg) twice daily. The evaluation of postinhalation FEV1 at 1 h after treatment was conducted on days 28, 56, and 84.
Result
Patients in the IND/GLY sequence showed significantly higher FEV1, 1 h postinhalation than those in TRP/FOR. A higher proportion of the patients stated that they were very satisfied with IND/GLY versus TRP/FOR about dyspnea reduction and showed a significant improvement in CAT score. IND/GLY demonstrated a good safety and tolerability profile.
Conclusion
This study indicated that, beyond FEV1, important PROs as well as lung function improved with the use of long-acting IND/GLY combination when compared with TRP/FOR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Diseases, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India.
- Department of TB and Respiratory Diseases, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India.
- Department of Physiology, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India.
- Department of Radiodiagnosis, Jawaharlal Nehru Medical College and Hospital, AMU, Aligarh, Uttar Pradesh, India.
Zitieren
APA
Shabbir, J., Masood, I., Waseem, S. M. A., & Masood, S. Y. (2025). To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 µg + Glycopyrrinium 50 µg versus Tiotropium 9 µg + Formoterol 12 µg in Patients with Chronic Obstructive Airway Disease. Annals of African Medicine. https://doi.org/10.4103/aam.aam_120_24
Vancouver
Shabbir J, Masood I, Waseem SMA, Masood SY. To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 µg + Glycopyrrinium 50 µg versus Tiotropium 9 µg + Formoterol 12 µg in Patients with Chronic Obstructive Airway Disease. Annals of African Medicine. 2025. doi:10.4103/aam.aam_120_24
BibTeX
@article{Shabbir2025,
author = {Shabbir, Javeeria and Masood, Imrana and Waseem, Shah Mohd Abbas and Masood, Syed Yusuf},
title = {To Study the Safety and Efficacy of Fixed Dose Combination of Indacaterolmaleate 110 µg + Glycopyrrinium 50 µg versus Tiotropium 9 µg + Formoterol 12 µg in Patients with Chronic Obstructive Airway Disease},
journal = {Annals of African Medicine},
year = {2025},
doi = {10.4103/aam.aam_120_24}
}
EUVIMED